RecruitingNCT06890013

A Prospective, Single-center, Observational Study Aiming to Assess the Predictive Role of Flow Mediated Dilatation in Acute Coronary Syndromes, Combined With Echocardiographic and Biochemical Indices

Identifying the Role of Flow Mediated Dilatation Assessment in Acute Coronary Syndromes - Evaluation of the Cor-IS Technology (the FLARE-ACS Trial)

Sponsor

Aristotle University Of Thessaloniki

Enrollment

100 participants

Start Date

Jun 1, 2024

Study Type

OBSERVATIONAL

Conditions

Acute Coronary Syndromes Flow Mediated Dilation Endothelial Function (FMD)

Summary

A prospective, single-center, observational study aiming to assess the predictive role of flow mediated dilatation in acute coronary syndromes, combined with echocardiographic and biochemical indices. The novel Cor-IS technology will also be evaluated.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

Age \> 18 years
Patients hospitalized due to acute coronary syndrome (STEMI, NSTEMI)
Capability of providing written informed consent
Patients able to comply with the follow-up schedule of the study

Exclusion Criteria12

Patients with acute coronary syndromes classified as MINOCA, or type II myocardial infarction
Patients with rare acute coronary syndrome types, such as spontaneous coronary artery dissection or Takotsubo syndrome
Patients with congenital heart disease
Age \> 85 years
Patients with end stage chronic kidney disease
Patients with active malignancy or autoimmune diseases which limit their survival
Patients with expected survival \< 1 year due to other reasons
Suboptimal echocardiographic windows
Inability to provide written consent
Inability to comply with the follow-up schedule of the study
Pregnancy
Use of intravenous drugs

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTObservation group

Patients with acute coronary syndrome undergo endothelial function assessment using two methods (flow mediated dilatation of the brachial artery and Cor-Is technology) transthoracic echocardiogram and plasma biomarkers' measurement.